The Latest Breaking News from Merck

Patient groups should be playing a central role in Canada’s health-care system, advocating for their members by promoting the visibility of their conditions, pushing for more rapid and accurate diagnoses and lobbying for the introduction and funding of new treatments and drugs that may help relieve their members’ symptoms and…

Indexes were mixed early Wednesday. Nvidia added gains after clearing a trendline entry on Tuesday. Trump Media & Technology soared.

Summit Therapeutics stock rocketed again Thursday — adding onto an 85% gain this week — after raising $235 million in a private placement.

Merck stock tumbled Monday after Summit Therapeutics' cancer drug outperformed blockbuster Keytruda in a study of lung cancer patients.

Letter signers include Yelp, Snap and Box CEOs, media empire heir James Murdoch, former CEOs of PepsiCo, Lyft and Merck

Merck & Co. has underperformed the healthcare sector this year, but Wall Street analysts are bullish about the stock prospects.

With advancements in biomedical sciences and promising drug pipelines, the healthcare industry is set for substantial growth in the coming years. Hence, investors might find opportunities in adding UnitedHealth Group (UNH), Merck & Co. (MRK), and Pfizer (PFE) to their portfolios for potential gains this year. Read on….

Diabetes treatments from Merck, Novo Nordisk and AstraZeneca will face the steepest cuts under the IRA, a list showed Thursday.

Merck stock has been struggling since the July 30 earnings announcement and could provide a nice bearish candidate.